No Data
No Data
After falling to an 11-year low and consolidating for several months, should I buy or sell pfizer (PFE.US) now?
In April of this year, Pfizer's (PFE.US) stock price fell to its lowest point since January 2013. As of the closing of July 1st, the stock has risen by about 11% since then; after falling to an 11-year low, Pfizer has been in a consolidation phase for several months. So, should you sell or buy Pfizer stocks now? From a fundamental perspective, Pfizer is still trying to overcome the drag of the cooling of its COVID-19 product and pushing forward the development of non-COVID-19 drug businesses. Recently, the company announced positive results from trials of two cancer drugs, but also closed a gene therapy program, and its stock price continues to range. In a study, patients received Pfizer's Elrex
(NVAX) - Analyzing Novavax's Short Interest
Novavax's (NYSE:NVAX) short percent of float has risen 3.9% since its last report. The company recently reported that it has 39.71 million shares sold short, which is 34.36% of all regular shares that
COVID Infections Could Be Seeing a Summer Surge Based on CDC Data
Express News | Novavax Inc - Intends to Have Its Vaccine Available in Canada for Immediate Release Post-Authorization
Express News | Novavax Submits Application to Health Canada for Updated Protein-Based 2024-2025 Formula Covid-19 Vaccine
Novavax Submits Application to Health Canada for Updated Protein-based 2024-2025 Formula COVID-19 Vaccine
Novavax's COVID-19 vaccine would be the only protein-based option available in Canada, if authorizedNovavax's filing is aligned with NACI, U.S. FDA, EMA and WHO recommendations on vaccine compositionG
No Data